• Publications
  • Influence
The TSC-mTOR signaling pathway regulates the innate inflammatory response.
It is shown that the tuberous sclerosis complex-mammalian target of rapamycin (TSC-mTOR) pathway regulated inflammatory responses after bacterial stimulation in monocytes, macrophages, and primary dendritic cells, and protected genetically susceptible mice against lethal Listeria monocytogenes infection. Expand
A Versatile Role of Mammalian Target of Rapamycin in Human Dendritic Cell Function and Differentiation
Divergent roles of mTOR during activation and differentiation of myeloid DCs and monocyte-derived DCs are demonstrated and it is found that kidney transplant patients treated with rapamycin displayed an increased immunostimulatory potential of mDCs compared with patients treating with calcineurin inhibitors. Expand
Roles of Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure.
Plasma angiotensin peptides represent a dynamic network that is altered in HF and in response to rhACE2, and an increased plasma Ang-(1-7) level is linked to ACE inhibitor use, whereas acute HF reduced Ang-2 levels and suppressed the Ang-7/Ang II ratio. Expand
Human recombinant soluble ACE2 in severe COVID-19
It is shown that hrsACE2 can reduce SARS-CoV-2 load by a factor of 1000–5000 in in-vitro cell-culture experiments and engineered organoids, directly demonstrating that ACE2 can effectively neutralise Sars-Cov-2. Expand
Pharmacokinetics and Pharmacodynamics of Recombinant Human Angiotensin-Converting Enzyme 2 in Healthy Human Subjects
A first-in-man study to determine pharmacokinetics, pharmacodynamics, safety, and tolerability of recombinant ACE2 in healthy volunteers found it well tolerated by healthy human subjects. Expand
Clinical Relevance and Role of Neuronal AT1 Receptors in ADAM17-Mediated ACE2 Shedding in Neurogenic Hypertension
It is demonstrated that angiotensin II type 1 receptors promote ADAM17-mediated ACE2 shedding in the brain of hypertensive patients, leading to a loss in compensatory activity during neurogenic hypertension. Expand
The versatility of HDL: a crucial anti‐inflammatory regulator
Eur J Clin Invest 2010; 40 (12): 1131–1143
Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure
New therapies in preclinical and early clinical stages of development are focused on, including novel small molecule inhibitors and receptor agonists/antagonists, less conventional strategies such as gene therapy to suppress angiotensinogen at the RNA level, recombinant ACE2 protein, and novel bispecific designer peptides. Expand
Murine Recombinant Angiotensin-Converting Enzyme 2: Effect on Angiotensin II–Dependent Hypertension and Distinctive Angiotensin-Converting Enzyme 2 Inhibitor Characteristics on Rodent and Human
Sustained elevations in serum ACE2 activity can be accomplished with murine ACE2 administration, thereby providing a strategy for ACE2 amplification in chronic studies using rodent models of hypertension and cardiovascular disease. Expand
Pharmacodynamic effects of C-domain-specific ACE inhibitors on the renin-angiotensin system in myocardial infarcted rats
LisW-S is able to effectively block ACE in vivo by C-domain-selective inhibition in different pathophysiological conditions as determined by circulating and equilibrium peptide level analysis. Expand